Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response
Natacha Colliou(University of Florida), Philippe Musette(Université Sorbonne Paris Nord), Frédérique Caillot(Inserm), Philippe Bernard(Hôpital Dupuytren), S. Oro(Hôpitaux Universitaires Henri-Mondor), M.‐S. Doutre(Hôpital Saint-André), Rüdiger Eming(Philipps University of Marburg), Emmanuelle Tancrède‐Bohin(Saint Louis University Hospital), F. Caux(Assistance Publique – Hôpitaux de Paris), M Sigal(Centre Hospitalier Victor Dupouy), Michael Hertl(Universitätsklinikum Gießen und Marburg), Brigitte Lemercier(Inserm), Serge Jacquot(Inserm), Maud Maho‐Vaillant(Inserm), P. Joly(Inserm), Sébastien Calbo(Inserm), Cathérine Prost(Université Sorbonne Paris Nord), Brigitte Le Mauff(Université de Caen Normandie), O. Chosidow(Sorbonne Université), I. Templier(Centre Hospitalier Universitaire de Grenoble), Stéphanie Le Corre(Harvard University), M. D’Incan(Centre Hospitalier Universitaire de Clermont-Ferrand), D Picard(Inserm), Nathalie Franck(Hôpital Cochin), Catherine Picard(Assistance Publique – Hôpitaux de Paris), Jean‐Claude Roujeau(Université Paris-Est Créteil), E. Delaporte(Université de Lille), Brigitte Dréno(Nantes Université), Christine Pauwels(iXBlue (France)), C. Bédane(Central Michigan University)
Cited by 246
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k